Targeting myocardial remodelling to develop novel therapies for heart failure: A position paper from the Working Group on Myocardial Function of the European Society of Cardiology

European Journal of Heart Failure

Volumn 16, Issue 5, 2014, Pages 494-508

  Tarone, Guido ^a   Balligand, Jean Luc ^b   Bauersachs, Johann ^c   Clerk, Angela ^d   De Windt, Leon ^e   Heymans, Stephane ^e   Hilfiker Kleiner, Denise ^c   Hirsch, Emilio ^a   Iaccarino, Guido ^f,g   Knöll, Ralph ^h   Leite Moreira, Adelino F ⁱ   Lourenço, André P ⁱ   Mayr, Manuel ^j   Thum, Thomas ^c,h   Tocchetti, Carlo G ^k  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY OF READING   (United Kingdom)

^e MAASTRICHT UNIVERSITY   (Netherlands)

^f UNIVERSITY OF SALERNO   (Italy)

^g IRCCS MULTIMEDICA   (Italy)

^h NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

ⁱ University of Porto   (Portugal)

^j KING'S COLLEGE LONDON   (United Kingdom)

^k Clinica Montevergine   (Italy)

more..

Author keywords

Adaptive hypertrophy; Cardiac remodelling; Cardiomyocyte survival; Contractility; Heart failure

Indexed keywords

ANGIOTENSIN; BETA ADRENERGIC RECEPTOR; BROMOCRIPTINE; CYCLOSPORIN A; DIURETIC AGENT; NEU DIFFERENTIATION FACTOR; NITRIC OXIDE DONOR; OMECAMTIV MECARBIL; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; VASODILATOR AGENT; CYCLOSPORIN; NEW DRUG; UREA;

CARDIOLOGY; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; MEDICAL SOCIETY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SARCOMERE; ANALOGS AND DERIVATIVES; CELL SURVIVAL; DRUG EFFECTS; HEART CONTRACTION; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; HYPERTROPHY, LEFT VENTRICULAR; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TRANSLATIONAL RESEARCH;

CELL SURVIVAL; CYCLOSPORINE; DRUGS, INVESTIGATIONAL; HEART FAILURE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; TRANSLATIONAL MEDICAL RESEARCH; UREA; VENTRICULAR REMODELING;

EID: 84899490402     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.62     Document Type: Review

References (124)

1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P,. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-869.
2. Ardehali H, Sabbah HN, Burke MA, Sarma S, Liu PP, Cleland JG, Maggioni A, Fonarow GC, Abel ED, Campia U, Gheorghiade M,. Targeting myocardial substrate metabolism in heart failure: potential for new therapies. Eur J Heart Fail 2012; 14: 120-129.
3. Ciccarelli M, Santulli G, Pascale V, Trimarco B, Iaccarino G,. Adrenergic receptors and metabolism: role in development of cardiovascular disease. Front Physiol 2013; 4: 265.
4. Ciccarelli M, Chuprun JK, Rengo G, Gao E, Wei Z, Peroutka RJ, Gold JI, Gumpert A, Chen M, Otis NJ, Dorn GW 2nd, Trimarco B, Iaccarino G, Koch WJ,. G protein-coupled receptor kinase 2 activity impairs cardiac glucose uptake and promotes insulin resistance after myocardial ischemia. Circulation 2011; 123: 1953-1962.
5. Thal DM, Yeow RY, Schoenau C, Huber J, Tesmer JJ,. Molecular mechanism of selectivity among G protein-coupled receptor kinase 2 inhibitors. Mol Pharmacol 2011; 80: 294-303.
6. Ciccarelli M, Cipolletta E, Iaccarino G,. GRK2 at the control shaft of cellular metabolism. Curr Pharm Des 2012; 18:121-127.
7. Perino A, Ghigo A, Ferrero E, Morello F, Santulli G, Baillie GS, Damilano F, Dunlop AJ, Pawson C, Walser R, Levi R, Altruda F, Silengo L, Langeberg LK, Neubauer G, Heymans S, Lembo G, Wymann MP, Wetzker R, Houslay MD, Iaccarino G, Scott JD, Hirsch E,. Integrating cardiac PIP3 and cAMP signaling through a PKA anchoring function of p110gamma. Mol Cell 2011; 42: 84-95.
8. Ghigo A, Perino A, Mehel H, Zahradnikova A Jr, Morello F, Leroy J, Nikolaev VO, Damilano F, Cimino J, De Luca E, Richter W, Westenbroek R, Catterall WA, Zhang J, Yan C, Conti M, Gomez AM, Vandecasteele G, Hirsch E, Fischmeister R,. Phosphoinositide 3-kinase gamma protects against catecholamine-induced ventricular arrhythmia through protein kinase A-mediated regulation of distinct phosphodiesterases. Circulation 2012; 126: 2073-2083.
9. Naga Prasad SV, Esposito G, Mao L, Koch WJ, Rockman HA,. Gbetagamma-dependent phosphoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy. J Biol Chem 2000; 275: 4693-4698.
10. Naga Prasad SV, Jayatilleke A, Madamanchi A, Rockman HA,. Protein kinase activity of phosphoinositide 3-kinase regulates beta-adrenergic receptor endocytosis. Nat Cell Biol 2005; 7: 785-796.
11. Damilano F, Franco I, Perrino C, Schaefer K, Azzolino O, Carnevale D, Cifelli G, Carullo P, Ragona R, Ghigo A, Perino A, Lembo G, Hirsch E,. Distinct effects of leukocyte and cardiac phosphoinositide 3-kinase gamma activity in pressure overload-induced cardiac failure. Circulation 2011; 123: 391-399.
12. Dessy C, Moniotte S, Ghisdal P, Havaux X, Noirhomme P, Balligand JL,. Endothelial beta3-adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization. Circulation 2004; 110: 948-954.
13. Moniotte S, Kobzik L, Feron O, Trochu JN, Gauthier C, Balligand JL,. Upregulation of beta(3)-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation 2001; 103: 1649-1655.
14. Idigo WO, Reilly S, Zhang MH, Zhang YH, Jayaram R, Carnicer R, Crabtree MJ, Balligand JL, Casadei B,. Regulation of endothelial nitric-oxide synthase (NOS) S-glutathionylation by neuronal NOS: evidence of a functional interaction between myocardial constitutive NOS isoforms. J Biol Chem 2012; 287: 43665-43673.
15. Belge C, Hammond J, Dubois-Deruy E, Manoury B, Hamelet J, Beauloye C, Markl A, Pouleur AC, Bertrand L, Esfahani H, Jnaoui K, Gotz KR, Nikolaev VO, Vanderper A, Herijgers P, Lobysheva I, Iaccarino G, Hilfiker-Kleiner D, Tavernier G, Langin D, Dessy C, Balligand JL,. Enhanced expression of β3-adrenoceptors in cardiac myocytes attenuates neurohormone-induced hypertrophic remodeling through nitric oxide synthase. Circulation 2013; in press.
16. Dessy C, Saliez J, Ghisdal P, Daneau G, Lobysheva II, Frérart F, Belge C, Jnaoui K, Noirhomme P, Feron O, Balligand JL,. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation 2005; 112: 1198-1205.
17. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Böhm M, Anker SD, Thompson SG, Poole-Wilson PA, Investigators S,. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215-225.
18. Sorrentino SA, Doerries C, Manes C, Speer T, Dessy C, Lobysheva I, Mohmand W, Akbar R, Bahlmann F, Besler C, Schaefer A, Hilfiker-Kleiner D, Lüscher TF, Balligand JL, Drexler H, Landmesser U,. Nebivolol exerts beneficial effects on endothelial function, early endothelial progenitor cells, myocardial neovascularization, and left ventricular dysfunction early after myocardial infarction beyond conventional β1-blockade. J Am Coll Cardiol 2011; 57: 601-611.
19. Ozakca I, Arioglu-Inan E, Esfahani H, Altan VM, Balligand JL, Kayki-Mutlu G, Ozcelikay AT,. Nebivolol prevents desensitization of β-adrenoceptor signaling and induction of cardiac hypertrophy in response to isoprenaline beyond β1-adrenoceptor blockage. Am J Physiol Heart Circ Physiol 2013; 304: H1267-H1276.
20. Pokreisz P, Vandenwijngaert S, Bito V, Van den Bergh A, Lenaerts I, Busch C, Marsboom G, Gheysens O, Vermeersch P, Biesmans L, Liu X, Gillijns H, Pellens M, Van Lommel A, Buys E, Schoonjans L, Vanhaecke J, Verbeken E, Sipido K, Herijgers P, Bloch KD, Janssens SP,. Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation 2009; 119: 408-416.
21. Lee DI, Kass DA,. Phosphodiesterases and cyclic GMP regulation in heart muscle. Physiology (Bethesda) 2012; 27: 248-258.
22. Guazzi M, Vicenzi M, Arena R, Guazzi MD,. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail 2011; 4: 8-17.
23. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E, Trial R,. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013; 309: 1268-1277.
24. Zhang Y, Tocchetti CG, Krieg T, Moens AL,. Oxidative and nitrosative stress in the maintenance of myocardial function. Free Radic Biol Med 2012; 53: 1531-1540.
25. Tocchetti CG, Stanley BA, Murray CI, Sivakumaran V, Donzelli S, Mancardi D, Pagliaro P, Gao WD, van Eyk J, Kass DA, Wink DA, Paolocci N,. Playing with cardiac 'redox switches': the 'HNO way' to modulate cardiac function. Antioxid Redox Signal 2011; 14: 1687-1698.
26. Sabbah HN, Tocchetti CG, Wang M, Daya S, Gupta RC, Tunin RS, Mazhari R, Takimoto E, Paolocci N, Cowart D, Colucci WS, Kass DA,. Nitroxyl (HNO) a novel approach for the acute treatment of heart failure. Circ Heart Fail 2013; 6: 1250-1258.
27. Marks AR,. Calcium cycling proteins and heart failure: mechanisms and therapeutics. J Clin Invest 2013; 123: 46-52.
28. Hulot JS, Senyei G, Hajjar RJ,. Sarcoplasmic reticulum and calcium cycling targeting by gene therapy. Gene Ther 2012; 19: 596-599.
29. Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, Yaroshinsky A, Zsebo KM, Dittrich H, Hajjar RJ,. Investigators CUbPAoGTiCDC. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2 + -ATPase in patients with advanced heart failure. Circulation 2011; 124: 304-313.
30. Malik FI, Hartman JJ, Elias KA, Morgan BP, Rodriguez H, Brejc K, Anderson RL, Sueoka SH, Lee KH, Finer JT, Sakowicz R, Baliga R, Cox DR, Garard M, Godinez G, Kawas R, Kraynack E, Lenzi D, Lu PP, Muci A, Niu C, Qian X, Pierce DW, Pokrovskii M, Suehiro I, Sylvester S, Tochimoto T, Valdez C, Wang W, Katori T, Kass DA, Shen YT, Vatner SF, Morgans DJ,. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science 2011; 331: 1439-1443.
31. Shen YT, Malik FI, Zhao X, Depre C, Dhar SK, Abarzúa P, Morgans DJ, Vatner SF,. Improvement of cardiac function by a cardiac myosin activator in conscious dogs with systolic heart failure. Circ Heart Fail 2010; 3: 522-527.
32. Cleland JG, Teerlink JR, Senior R, Nifontov EM, Mc Murray JJ, Lang CC, Tsyrlin VA, Greenberg BH, Mayet J, Francis DP, Shaburishvili T, Monaghan M, Saltzberg M, Neyses L, Wasserman SM, Lee JH, Saikali KG, Clarke CP, Goldman JH, Wolff AA, Malik FI,. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet 2011; 378: 676-683.
33. Thum T, Catalucci D, Bauersachs J,. MicroRNAs: novel regulators in cardiac development and disease. Cardiovasc Res 2008; 79: 562-570.
34. Callis TE, Pandya K, Seok HY, Tang RH, Tatsuguchi M, Huang ZP, Chen JF, Deng Z, Gunn B, Shumate J, Willis MS, Selzman CH, Wang DZ,. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest 2009; 119: 2772-2786.
35. Montgomery RL, Hullinger TG, Semus HM, Dickinson BA, Seto AG, Lynch JM, Stack C, Latimer PA, Olson EN, van Rooij E,. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 2011; 124: 1537-1547.
36. da Costa Martins PA, Salic K, Gladka MM, Armand AS, Leptidis S, el Azzouzi H, Hansen A, Coenen-de Roo CJ, Bierhuizen MF, van der Nagel R, van Kuik J, de Weger R, de Bruin A, Condorelli G, Arbones ML, Eschenhagen T, De Windt LJ,. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nat Cell Biol 2010; 12: 1220-1227.
37. Haghikia A, Missol-Kolka E, Tsikas D, Venturini L, Brundiers S, Castoldi M, Muckenthaler MU, Eder M, Stapel B, Thum T, Petrasch-Parwez E, Drexler H, Hilfiker-Kleiner D, Scherr M,. Signal transducer and activator of transcription 3-mediated regulation of miR-199a-5p links cardiomyocyte and endothelial cell function in the heart: a key role for ubiquitin-conjugating enzymes. Eur Heart J 2011; 32: 1287-1297.
38. Ucar A, Gupta SK, Fiedler J, Erikci E, Kardasinski M, Batkai S, Dangwal S, Kumarswamy R, Bang C, Holzmann A, Remke J, Caprio M, Jentzsch C, Engelhardt S, Geisendorf S, Glas C, Hofmann TG, Nessling M, Richter K, Schiffer M, Carrier L, Napp LC, Bauersachs J, Chowdhury K, Thum T,. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun 2012; 3: 1078.
39. Heymans S, Corsten MF, Verhesen W, Carai P, van Leeuwen RE, Custers K, Peters T, Hazebroek M, Stoger L, Wijnands E, Janssen BJ, Creemers EE, Pinto YM, Grimm D, Schurmann N, Vigorito E, Thum T, Stassen F, Yin X, Mayr M, de Windt LJ, Lutgens E, Wouters K, de Winther MP, Zacchigna S, Giacca M, van Bilsen M, Papageorgiou AP, Schroen B,. Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation 2013; 128: 1420-1432.
40. Hullinger TG, Montgomery RL, Seto AG, Dickinson BA, Semus HM, Lynch JM, Dalby CM, Robinson K, Stack C, Latimer PA, Hare JM, Olson EN, van Rooij E,. Inhibition of miR-15 protects against cardiac ischemic injury. Circ Res 2012; 110: 71-81.
41. Whelan RS, Kaplinskiy V, Kitsis RN,. Cell death in the pathogenesis of heart disease: mechanisms and significance. Annu Rev Physiol 2010; 72: 19-44.
42. Kung G, Konstantinidis K, Kitsis RN,. Programmed necrosis, not apoptosis, in the heart. Circ Res 2011; 108: 1017-1036.
43. Dickens LS, Powley IR, Hughes MA, MacFarlane M,. The 'complexities' of life and death: death receptor signalling platforms. Exp Cell Res 2012; 318: 1269-1277.
44. Smith CC, Yellon DM,. Necroptosis, necrostatins and tissue injury. J Cell Mol Med 2011; 15: 1797-1806.
45. Oerlemans MI, Liu J, Arslan F, den Ouden K, van Middelaar BJ, Doevendans PA, Sluijter JP,. Inhibition of RIP1-dependent necrosis prevents adverse cardiac remodeling after myocardial ischemia-reperfusion in vivo. Basic Res Cardiol 2012; 107: 270.
46. Takahashi N, Duprez L, Grootjans S, Cauwels A, Nerinckx W, DuHadaway JB, Goossens V, Roelandt R, Van Hauwermeiren F, Libert C, Declercq W, Callewaert N, Prendergast GC, Degterev A, Yuan J, Vandenabeele P,. Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models. Cell Death Dis 2012; 3: e437.
47. Di Lisa F, Carpi A, Giorgio V, Bernardi P,. The mitochondrial permeability transition pore and cyclophilin D in cardioprotection. Biochim Biophys Acta 1813; 2011: 1316-1322.
48. Hausenloy DJ, Boston-Griffiths EA, Yellon DM,. Cyclosporin A and cardioprotection: from investigative tool to therapeutic agent. Br J Pharmacol 2012; 165: 1235-1245.
49. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, Elbelghiti R, Cung TT, Bonnefoy E, Angoulvant D, Macia C, Raczka F, Sportouch C, Gahide G, Finet G, André-Fouët X, Revel D, Kirkorian G, Monassier JP, Derumeaux G, Ovize M,. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008; 359: 473-481.
50. Eschenhagen T, Force T, Ewer MS, de Keulenaer GW, Suter TM, Anker SD, Avkiran M, de Azambuja E, Balligand JL, Brutsaert DL, Condorelli G, Hansen A, Heymans S, Hill JA, Hirsch E, Hilfiker-Kleiner D, Janssens S, de Jong S, Neubauer G, Pieske B, Ponikowski P, Pirmohamed M, Rauchhaus M, Sawyer D, Sugden PH, Wojta J, Zannad F, Shah AM,. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2011; 13: 1-10.
51. Liu X, Gu X, Li Z, Li X, Li H, Chang J, Chen P, Jin J, Xi B, Chen D, Lai D, Graham RM, Zhou M,. Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol 2006; 48: 1438-1447.
52. Gao R, Zhang J, Cheng L, Wu X, Dong W, Yang X, Li T, Liu X, Xu Y, Li X, Zhou M,. A phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cardiol 2010; 55: 1907-1914.
53. Jabbour A, Hayward CS, Keogh AM, Kotlyar E, McCrohon JA, England JF, Amor R, Liu X, Li XY, Zhou MD, Graham RM, Macdonald PS,. Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. Eur J Heart Fail 2011; 13: 83-92.
54. Willis MS, Patterson C,. Proteotoxicity and cardiac dysfunction- Alzheimer's disease of the heart? N Engl J Med 2013; 368: 455-464.
55. Rajasekaran NS, Varadharaj S, Khanderao GD, Davidson CJ, Kannan S, Firpo MA, Zweier JL, Benjamin IJ,. Sustained activation of nuclear erythroid 2-related factor 2/antioxidant response element signaling promotes reductive stress in the human mutant protein aggregation cardiomyopathy in mice. Antioxid Redox Signal 2011; 14: 957-971.
56. Kumarapeli AR, Su H, Huang W, Tang M, Zheng H, Horak KM, Li M, Wang X,. Alpha B-crystallin suppresses pressure overload cardiac hypertrophy. Circ Res 2008; 103: 1473-1482.
57. Fan GC, Kranias EG,. Small heat shock protein 20 (HspB6) in cardiac hypertrophy and failure. J Mol Cell Cardiol 2011; 51: 574-577.
58. Danan IJ, Rashed ER, Depre C,. Therapeutic potential of H11 kinase for the ischemic heart. Cardiovasc Drug Rev. 2007; 25: 14-29.
59. Qiu H, Lizano P, Laure L, Sui X, Rashed E, Park JY, Hong C, Gao S, Holle E, Morin D, Dhar SK, Wagner T, Berdeaux A, Tian B, Vatner SF, Depre C,. H11 kinase/heat shock protein 22 deletion impairs both nuclear and mitochondrial functions of STAT3 and accelerates the transition into heart failure on cardiac overload. Circulation 2011; 124: 406-415.
60. Ferretti R, Sbroggiò M, Di Savino A, Fusella F, Bertero A, Michowski W, Tarone G, Brancaccio M,. Morgana and melusin: two fairies chaperoning signal transduction. Cell Cycle 2011; 10: 3678-3683.
61. De Acetis M, Notte A, Accornero F, Selvetella G, Brancaccio M, Vecchione C, Sbroggiò M, Collino F, Pacchioni B, Lanfranchi G, Aretini A, Ferretti R, Maffei A, Altruda F, Silengo L, Tarone G, Lembo G,. Cardiac overexpression of melusin protects from dilated cardiomyopathy due to long-standing pressure overload. Circ Res 2005; 96: 1087-1094.
62. Gamerdinger M, Carra S, Behl C,. Emerging roles of molecular chaperones and co-chaperones in selective autophagy: focus on BAG proteins. J Mol Med (Berl) 2011; 89: 1175-1182.
63. Arimura T, Ishikawa T, Nunoda S, Kawai S, Kimura A,. Dilated cardiomyopathy-associated BAG3 mutations impair Z-disc assembly and enhance sensitivity to apoptosis in cardiomyocytes. Hum Mutat 2011; 32: 1481-1491.
64. Sakabe M, Shiroshita-Takeshita A, Maguy A, Brundel BJ, Fujiki A, Inoue H, Nattel S,. Effects of a heat shock protein inducer on the atrial fibrillation substrate caused by acute atrial ischaemia. Cardiovasc Res 2008; 78: 63-70.
65. Willis MS, Patterson C,. Into the heart: the emerging role of the ubiquitin-proteasome system. J Mol Cell Cardiol 2006; 41: 567-579.
66. Knoll R, Linke WA, Zou P, Miocic S, Kostin S, Buyandelger B, Ku CH, Neef S, Bug M, Schafer K, Knoll G, Felkin LE, Wessels J, Toischer K, Hagn F, Kessler H, Didie M, Quentin T, Maier LS, Teucher N, Unsold B, Schmidt A, Birks EJ, Gunkel S, Lang P, Granzier H, Zimmermann WH, Field LJ, Faulkner G, Dobbelstein M, Barton PJ, Sattler M, Wilmanns M, Chien KR,. Telethonin deficiency is associated with maladaptation to biomechanical stress in the mammalian heart. Circ Res 2011; 109: 758-769.
67. Li W, Bengtson MH, Ulbrich A, Matsuda A, Reddy VA, Orth A, Chanda SK, Batalov S, Joazeiro CA,. Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle's dynamics and signaling. PLoS One 2008; 3: e1487.
68. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S,. The protein kinase complement of the human genome. Science 2002; 298: 1912-1934.
69. Rose BA, Force T, Wang Y,. Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev 2010; 90: 1507-1546.
70. Soga M, Matsuzawa A, Ichijo H,. Oxidative stress-induced diseases via the ASK1 signaling pathway. Int J Cell Biol 2012; 2012: 439587.
71. Cargnello M, Roux PP,. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 2011; 75: 50-83.
72. Aye TT, Scholten A, Taouatas N, Varro A, Van Veen TA, Vos MA, Heck AJ,. Proteome-wide protein concentrations in the human heart. Mol Biosyst 2010; 6: 1917-1927.
73. Delpire E,. The mammalian family of sterile 20p-like protein kinases. Pflugers Arch 2009; 458: 953-967.
74. Sheehan KA, Ke Y, Solaro RJ,. p21-activated kinase-1 and its role in integrated regulation of cardiac contractility. Am J Physiol Regul Integr Comp Physiol 2007; 293: R963-R973.
75. Odashima M, Usui S, Takagi H, Hong C, Liu J, Yokota M, Sadoshima J,. Inhibition of endogenous Mst1 prevents apoptosis and cardiac dysfunction without affecting cardiac hypertrophy after myocardial infarction. Circ Res 2007; 100: 1344-1352.
76. Mercier-Zuber A, O'Shaughnessy KM,. Role of SPAK and OSR1 signalling in the regulation of NaCl cotransporters. Curr Opin Nephrol Hypertens 2011; 20: 534-540.
77. Fuller SJ, McGuffin LJ, Marshall AK, Giraldo A, Pikkarainen S, Clerk A, Sugden PH,. A novel non-canonical mechanism of regulation of MST3 (mammalian Sterile20-related kinase 3). Biochem J 2012; 442: 595-610.
78. Sugden PH, McGuffin LJ, Clerk A,. SOcK, MiSTs, MASK and STicKs: the GCKIII (germinal centre kinase III) kinases and their heterologous protein-protein interactions. Biochem J 2013; 454: 13-30.
79. Wagner SM, Sabourin LA,. A novel role for the Ste20 kinase SLK in adhesion signaling and cell migration. Cell Adh Migr 2009; 3: 182-184.
80. Franchini KG,. Focal adhesion kinase-the basis of local hypertrophic signaling domains. J Mol Cell Cardiol 2012; 52: 485-492.
81. Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L,. Signal transduction by vascular endothelial growth factor receptors. Biochem J 2011; 437: 169-183.
82. Ahn A, Frishman WH, Gutwein A, Passeri J, Nelson M,. Therapeutic angiogenesis: a new treatment approach for ischemic heart disease-part I. Cardiol Rev 2008; 16: 163-171.
83. Hendel RC, Henry TD, Rocha-Singh K, Isner JM, Kereiakes DJ, Giordano FJ, Simons M, Bonow RO,. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation 2000; 101: 118-121.
84. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, Shah PK, Willerson JT, Benza RL, Berman DS, Gibson CM, Bajamonde A, Rundle AC, Fine J, McCluskey ER, Investigators V,. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 2003; 107: 1359-1365.
85. Rajagopalan S, Mohler E, Lederman RJ, Saucedo J, Mendelsohn FO, Olin J, Blebea J, Goldman C, Trachtenberg JD, Pressler M, Rasmussen H, Annex BH, Hirsch AT,. trial RAWVEGF. Regional Angiogenesis with Vascular Endothelial Growth Factor (VEGF) in peripheral arterial disease: design of the RAVE trial. Am Heart J 2003; 145: 1114-1118.
86. Pepe M, Mamdani M, Zentilin L, Csiszar A, Qanud K, Zacchigna S, Ungvari Z, Puligadda U, Moimas S, Xu X, Edwards JG, Hintze TH, Giacca M, Recchia FA,. Intramyocardial VEGF-B167 gene delivery delays the progression towards congestive failure in dogs with pacing-induced dilated cardiomyopathy. Circ Res 2010; 106: 1893-1903.
87. Iwasaki H, Kawamoto A, Tjwa M, Horii M, Hayashi S, Oyamada A, Matsumoto T, Suehiro S, Carmeliet P, Asahara T,. PlGF repairs myocardial ischemia through mechanisms of angiogenesis, cardioprotection and recruitment of myo-angiogenic competent marrow progenitors. PLoS One 2011; 6: e24872.
88. Carnevale D, Lembo G,. Placental growth factor and cardiac inflammation. Trends Cardiovasc Med 2012; 22: 209-212.
89. Bry M, Kivelä R, Holopainen T, Anisimov A, Tammela T, Soronen J, Silvola J, Saraste A, Jeltsch M, Korpisalo P, Carmeliet P, Lemström KB, Shibuya M, Ylä-Herttuala S, Alhonen L, Mervaala E, Andersson LC, Knuuti J, Alitalo K,. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation 2010; 122: 1725-1733.
90. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, Richardson JA, Bassel-Duby R, Olson EN,. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008; 15: 261-271.
91. van Solingen C, Seghers L, Bijkerk R, Duijs JM, Roeten MK, van Oeveren-Rietdijk AM, Baelde HJ, Monge M, Vos JB, de Boer HC, Quax PH, Rabelink TJ, van Zonneveld AJ,. Antagomir-mediated silencing of endothelial cell specific microRNA-126 impairs ischemia-induced angiogenesis. J Cell Mol Med 2009; 13: 1577-1585.
92. Hu S, Huang M, Li Z, Jia F, Ghosh Z, Lijkwan MA, Fasanaro P, Sun N, Wang X, Martelli F, Robbins RC, Wu JC,. MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation 2010; 122 (11 Suppl): S124-S131.
93. Patten IS, Rana S, Shahul S, Rowe GC, Jang C, Liu L, Hacker MR, Rhee JS, Mitchell J, Mahmood F, Hess P, Farrell C, Koulisis N, Khankin EV, Burke SD, Tudorache I, Bauersachs J, del Monte F, Hilfiker-Kleiner D, Karumanchi SA, Arany Z,. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 2012; 485: 333-338.
94. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, Forster O, Quint A, Landmesser U, Doerries C, Luchtefeld M, Poli V, Schneider MD, Balligand JL, Desjardins F, Ansari A, Struman I, Nguyen NQ, Zschemisch NH, Klein G, Heusch G, Schulz R, Hilfiker A, Drexler H,. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007; 128: 589-600.
95. Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema JP, Becker A, McMurray J, Yamac H, Labidi S, Struman I, Struhman I, Hilfiker-Kleiner D,. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation 2010; 121: 1465-1473.
96. Halkein J, Tabruyn SP, Ricke-Hoch M, Haghikia A, Nguyen NQ, Scherr M, Castermans K, Malvaux L, Lambert V, Thiry M, Sliwa K, Noel A, Martial JA, Hilfiker-Kleiner D, Struman I,. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest 2013; 123: 2143-2154.
97. Bonauer A, Carmona G, Iwasaki M, Mione M, Koyanagi M, Fischer A, Burchfield J, Fox H, Doebele C, Ohtani K, Chavakis E, Potente M, Tjwa M, Urbich C, Zeiher AM, Dimmeler S,. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009; 324: 1710-1713.
98. Hinkel R, Penzkofer D, Zühlke S, Fischer A, Husada W, Xu QF, Baloch E, van Rooij E, Zeiher AM, Kupatt C, Dimmeler S,. Inhibition of microRNA-92a protects against ischemia/reperfusion injury in a large-animal model. Circulation 2013; 128: 1066-1075.
99. Fiedler J, Jazbutyte V, Kirchmaier BC, Gupta SK, Lorenzen J, Hartmann D, Galuppo P, Kneitz S, Pena JT, Sohn-Lee C, Loyer X, Soutschek J, Brand T, Tuschl T, Heineke J, Martin U, Schulte-Merker S, Ertl G, Engelhardt S, Bauersachs J, Thum T,. MicroRNA-24 regulates vascularity after myocardial infarction. Circulation 2011; 124: 720-730.
100. Hoch M, Fischer P, Stapel B, Missol-Kolka E, Sekkali B, Scherr M, Favret F, Braun T, Eder M, Schuster-Gossler K, Gossler A, Hilfiker A, Balligand JL, Drexler H, Hilfiker-Kleiner D,. Erythropoietin preserves the endothelial differentiation capacity of cardiac progenitor cells and reduces heart failure during anticancer therapies. Cell Stem Cell 2011; 9: 131-143.
101. Horie T, Ono K, Nishi H, Nagao K, Kinoshita M, Watanabe S, Kuwabara Y, Nakashima Y, Takanabe-Mori R, Nishi E, Hasegawa K, Kita T, Kimura T,. Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway. Cardiovasc Res 2010; 87: 656-664.
102. Frangogiannis NG,. Matricellular proteins in cardiac adaptation and disease. Physiol Rev 2012; 92: 635-688.
103. Weber KT, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC,. Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat Rev Cardiol 2013; 10: 15-26.
104. Frolova EG, Sopko N, Blech L, Popovic ZB, Li J, Vasanji A, Drumm C, Krukovets I, Jain MK, Penn MS, Plow EF, Stenina OI,. Thrombospondin-4 regulates fibrosis and remodeling of the myocardium in response to pressure overload. FASEB J 2012; 26: 2363-2373.
105. Lynch JM, Maillet M, Vanhoutte D, Schloemer A, Sargent MA, Blair NS, Lynch KA, Okada T, Aronow BJ, Osinska H, Prywes R, Lorenz JN, Mori K, Lawler J, Robbins J, Molkentin JD,. A thrombospondin-dependent pathway for a protective ER stress response. Cell 2012; 149: 1257-1268.
106. Xie J, Wang J, Li R, Dai Q, Yong Y, Zong B, Xu Y, Li E, Ferro A, Xu B,. Syndecan-4 over-expression preserves cardiac function in a rat model of myocardial infarction. J Mol Cell Cardiol 2012; 53: 250-258.
107. Lõpez B, González A, Hermida N, Valencia F, de Teresa E, Díez J,. Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects. Am J Physiol Heart Circ Physiol 2010; 299: H1-H9.
108. Lõpez B, Querejeta R, González A, Beaumont J, Larman M, Díez J,. Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension. 2009; 53: 236-242.
109. Group TI,. Effects of prolonged-release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure: a randomized, blinded-end point, active-controlled study. Clin Ther 201; 1204-1213.e1203.
110. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, Castoldi M, Soutschek J, Koteliansky V, Rosenwald A, Basson MA, Licht JD, Pena JT, Rouhanifard SH, Muckenthaler MU, Tuschl T, Martin GR, Bauersachs J, Engelhardt S,. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008; 456: 980-984.
111. Adam O, Löhfelm B, Thum T, Gupta SK, Puhl SL, Schäfers HJ, Böhm M, Laufs U,. Role of miR-21 in the pathogenesis of atrial fibrosis. Basic Res Cardiol 2012; 107: 278.
112. Pan Z, Sun X, Shan H, Wang N, Wang J, Ren J, Feng S, Xie L, Lu C, Yuan Y, Zhang Y, Wang Y, Lu Y, Yang B,. MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-β1 pathway. Circulation 2012; 126: 840-850.
113. Salari K, Watkins H, Ashley EA,. Personalized medicine: hope or hype? Eur Heart J 2012; 33: 1564-1570.
114. Talameh JA, McLeod HL, Adams KF, Patterson JH,. Genetic tailoring of pharmacotherapy in heart failure: optimize the old, while we wait for something new. J Card Fail 2012; 18: 338-349.
115. Jensen BC, McLeod HL,. Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity. Pharmacogenomics 2013; 14: 205-213.
116. Gao WD, Murray CI, Tian Y, Zhong X, DuMond JF, Shen X, Stanley BA, Foster DB, Wink DA, King SB, Van Eyk JE, Paolocci N,. Nitroxyl-mediated disulfide bond
117. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN,. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 2007; 316: 575-579.
118. Gurusamy N, Lekli I, Gherghiceanu M, Popescu LM, Das DK,. BAG-1 induces autophagy for cardiac cell survival. Autophagy 2009; 5: 120-121.
119. Wang X, Tokuda H, Hatakeyama D, Hirade K, Niwa M, Ito H, Kato K, Kozawa O,. Mechanism of simvastatin on induction of heat shock protein in osteoblasts. Arch Biochem Biophys 2003; 415: 6-13.
120. Knöll R, Linke WA, Zou P, Miocic S, Kostin S, Buyandelger B, Ku CH, Neef S, Bug M, Schäfer K, Knöll G, Felkin LE, Wessels J, Toischer K, Hagn F, Kessler H, Didié M, Quentin T, Maier LS, Teucher N, Unsöld B, Schmidt A, Birks EJ, Gunkel S, Lang P, Granzier H, Zimmermann WH, Field LJ, Faulkner G, Dobbelstein M, Barton PJ, Sattler M, Wilmanns M, Chien KR,. Telethonin deficiency is associated with maladaptation to biomechanical stress in the mammalian heart. Circ Res 2011; 109: 758-769.
121. Ahn A, Frishman WH, Gutwein A, Passeri J, Nelson M,. Therapeutic angiogenesis: a new treatment approach for ischemic heart disease-Part II. Cardiol Rev 2008; 16: 219-229.
122. Vanhoutte D, Schellings MW, Götte M, Swinnen M, Herias V, Wild MK, Vestweber D, Chorianopoulos E, Cortés V, Rigotti A, Stepp MA, Van de Werf F, Carmeliet P, Pinto YM, Heymans S,. Increased expression of syndecan-1 protects against cardiac dilatation and dysfunction after myocardial infarction. Circulation 2007; 115: 475-482.
123. Schellings MW, Vanhoutte D, Swinnen M, Cleutjens JP, Debets J, van Leeuwen RE, d'Hooge J, Van de Werf F, Carmeliet P, Pinto YM, Sage EH, Heymans S,. Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction. J Exp Med 2009; 206: 113-123.
124. Cardin S, Guasch E, Luo X, Naud P, Le Quang K, Shi Y, Tardif JC, Comtois P, Nattel S,. Role for MicroRNA-21 in atrial profibrillatory fibrotic remodeling associated with experimental postinfarction heart failure. Circ Arrhythm Electrophysiol 2012; 5: 1027-1035.